BMP 655Alternative Names: BMP655; PF-05208762; PF5208762
Latest Information Update: 18 Aug 2011
At a glance
- Originator Wyeth
- Developer Pfizer
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Tendon injuries
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-I for Tendon injuries in Netherlands (Implant)
- 11 Aug 2011 Discontinued - Phase-I for Tendon injuries in Japan (Implant)
- 15 Oct 2009 Wyeth has been acquired by Pfizer